CBTN

GPC2 MAY BE AN IMMUNOTHERAPEUTIC TARGET IN HIGH-RISK NEUROBLASTOMA

Published in
American Association for Cancer Research
on
Bosse, KR, P Raman, Z Zhu, M Lane, D Martinez, and S Heitzeneder
aacr.jpg
Access the publication

Abstract

Major finding: A GPC2-targeting antibody–drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

Approach: An RNA-seq pipeline identifies candidate cell-surface targets specifically expressed in neuroblastoma.

Impact: Immunotherapeutic GPC2 targeting may be beneficial in high-risk neuroblastoma and other embryonal tumors.